Tyrosine Protein Kinase JAK3 - Pipeline Review, H1 2020

Published: January 2020
Pages: 138
Code: A1D559ABE9057A632B9D3815902A5846
Format: PDF
Publisher Global Markets Direct
From Add to basket
$ 3,500.00
According to the recently published report ''; Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 32 molecules.
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins.
The report '' outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 6, 1, 16 and 3 respectively. Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Musculoskeletal Disorders, Oncology, Respiratory, Ophthalmology and Cardiovascular which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Inflammatory Bowel Disease, Alopecia Areata, Psoriasis, Ulcerative Colitis, Vitiligo, Asthma, Crohn's Disease (Regional Enteritis), Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Dermatomyositis, Diffuse Large B-Cell Lymphoma, Inflammation, Systemic Lupus Erythematosus, Allergic Conjunctivitis, Anaplastic Large Cell Lymphoma (ALCL), Androgenic Alopecia, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Autoimmune Disorders, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cachexia, Celiac Disease, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Cutaneous T-Cell Lymphoma, Dermatitis (Eczema), Dermatosis, Fibrosis, Follicular Lymphoma, Ischemia Reperfusion Injury, Lung Transplant Rejection, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Myeloproliferative Disorders, Pemphigus Vulgaris, Peripheral T-Cell Lymphomas (PTCL), Polyarticular Juvenile Idiopathic Arthritis (PJIA), Pruritus, Psoriatic Arthritis, Sarcoidosis, Sarcopenia, Systemic Sclerosis (Scleroderma) and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Additonal Information

  • - The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
  • - The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • - The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • - The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • - The report summarizes all the dormant and discontinued pipeline projects
  • - The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics

Companies Mentioned

Aclaris Therapeutics Inc
Arrien Pharmaceuticals LLC
Astellas Pharma Inc
Bristol-Myers Squibb Co
Chipscreen Biosciences Ltd
Clevexel Pharma SAS
Daewoong Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Japan Tobacco Inc
KBP BioSciences Co Ltd
Merck & Co Inc
MYOS RENS Technology Inc
Oncostellae SL
Pfizer Inc
Portola Pharmaceuticals Inc
Sienna Biopharmaceuticals Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Identify the use of drugs for target identification and drug repurposing Identify potential new clients or partners in the target demographic Develop strategic initiatives by understanding the focus areas of leading companies Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Add to basket
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
  • Aclaris Therapeutics Inc
  • Arrien Pharmaceuticals LLC
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Chipscreen Biosciences Ltd
  • Clevexel Pharma SAS
  • Daewoong Pharmaceutical Co Ltd
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • Japan Tobacco Inc
  • KBP BioSciences Co Ltd
  • Merck & Co Inc
  • MYOS RENS Technology Inc
  • Oncostellae SL
  • Pfizer Inc
  • Portola Pharmaceuticals Inc
  • Sienna Biopharmaceuticals Inc
  • Simcere Pharmaceutical Group
  • Theravance Biopharma Inc
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles
  • ARN-4079 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ATI-1777 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products
  • Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Aclaris Therapeutics Inc, H1 2020
  • Pipeline by Arrien Pharmaceuticals LLC, H1 2020
  • Pipeline by Astellas Pharma Inc, H1 2020
  • Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Pipeline by Chipscreen Biosciences Ltd, H1 2020
  • Pipeline by Clevexel Pharma SAS, H1 2020
  • Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
  • Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2020
  • Pipeline by Japan Tobacco Inc, H1 2020
  • Pipeline by KBP BioSciences Co Ltd, H1 2020
  • Pipeline by Merck & Co Inc, H1 2020
  • Pipeline by MYOS RENS Technology Inc, H1 2020
  • Pipeline by Oncostellae SL, H1 2020
  • Pipeline by Pfizer Inc, H1 2020
  • Pipeline by Portola Pharmaceuticals Inc, H1 2020
  • Pipeline by Sienna Biopharmaceuticals Inc, H1 2020
  • Pipeline by Simcere Pharmaceutical Group, H1 2020
  • Pipeline by Theravance Biopharma Inc, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Dormant Products, H1 2020 (Contd..2), H1 2020
  • Dormant Products, H1 2020 (Contd..3), H1 2020
  • Discontinued Products, H1 2020
  • List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020

Keywords
;